These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 7208341

  • 1. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J, Sauvanet JP, Chanu B, Bakir R, Goy-Loeper J, Saya C, Pinaroli F.
    Nouv Presse Med; 1980 Dec 22; 9(49):3747-51. PubMed ID: 7208341
    [Abstract] [Full Text] [Related]

  • 2. [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
    Micheli H, Pometta D, Gustafson A.
    Nouv Presse Med; 1980 Dec 22; 9(49):3759-62. PubMed ID: 7208343
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.
    Nikkilä EA, Ylikahri R, Huttunen JK.
    Proc R Soc Med; 1976 Dec 22; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983 Dec 22; 33(8):1185-90. PubMed ID: 6685498
    [Abstract] [Full Text] [Related]

  • 10. [Beclobrate (Turec) in the treatment of primary hyperlipoproteinemia. II. Results of the treatment in relation to the type of hyperlipoproteinemia].
    Sznajd J, Idzior-Waluś B, Korzus G, Zabiński J, Hebda A, Markiewicz M.
    Przegl Lek; 1990 Dec 22; 47(10):711-4. PubMed ID: 2089450
    [Abstract] [Full Text] [Related]

  • 11. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
    Franceschini G, Sirtori M, Gianfranceschi G, Frosi T, Montanari G, Sirtori CR.
    Artery; 1985 Dec 22; 12(6):363-81. PubMed ID: 4051756
    [Abstract] [Full Text] [Related]

  • 12. [The effect of fenofibrate in various types of hyperlipoproteinemias].
    Sucić M.
    Lijec Vjesn; 1989 Mar 22; 111(3):93-7. PubMed ID: 2747411
    [Abstract] [Full Text] [Related]

  • 13. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M.
    Przegl Lek; 1984 Mar 22; 41(7):493-9. PubMed ID: 6390536
    [No Abstract] [Full Text] [Related]

  • 14. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ, Gutiérrez JA, Menéndez JA, Micó L, Muñoz M, de Oya M.
    Clin Ther; 1980 Mar 22; 3(3):219-26. PubMed ID: 7459931
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia.
    Feussner G, Kurth B, Lohrmann J.
    Eur J Med Res; 1997 Apr 21; 2(4):165-8. PubMed ID: 9110923
    [Abstract] [Full Text] [Related]

  • 19. [Long-term treatment of hyperlipoproteinaemia, types IIa and IIb, with etiroxate (author's transl)].
    Schwartzkopff W, Russ E.
    Dtsch Med Wochenschr; 1975 Apr 11; 100(15):815-21. PubMed ID: 164334
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.